Early results for ARV-102, a novel PROTAC LRRK2 degrader, show the experimental therapy is well-tolerated and demonstrates key biomarker engagement.
Tecentriq and Zepzelca combination approved as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC).
The approval of the twice-daily pill remibrutinib positions the company to challenge injectable treatments in a multi-billion dollar market.
Precious metal outpaces gold as shrinking stockpiles and soaring industrial demand fuel a powerful market rally.
Late-breaking trial results for obefazimod show significant efficacy, positioning the first-in-class oral therapy in a competitive market.
Proposed 'OBBBA' legislation would hike tax credits for new domestic chip plants to 35%, aiming to accelerate 'Made in America' initiatives.
Combination therapy approval for small cell lung cancer offers a new standard of care and a bullish signal for the pharmaceutical sector.
Landmark bill grants Uber and Lyft drivers collective bargaining rights, signaling a potential shift in the gig work model.